Sulgin Avexima 500 mg 20 tablets

bacterial dysentery;
colitis and enterocolitis;
preparation for surgery on the large intestine.

In acute dysentery, two treatment courses are conducted. First course: on days 1 and 2 - 1 g every 4 hours (total 6 g/day), days 3 and 4 - 1 g every 6 hours (4 g/day), days 5 and 6 - 1 g every 8 hours (3 g/day). If necessary, a second course is conducted after 5-6 days: days 1 and 2 - 1 g every 4 hours, at night - every 8 hours (total 5 g/day), days 3 and 4 - 1 g every 4 hours (4 g/day), no night dose, day 5 - 3 g/day.
For children over 3 years old - 0.5 g 4 times a day for 7 days.
For the treatment of other infections: adults - orally, 1-2 g every 4-6 hours; in the next 2-3 days - half doses.
For children over 3 years old - on the first day 0.1 g/kg/day in equal doses every 4 hours, on subsequent days - 0.25-0.5 g every 6-8 hours.
For the prevention of postoperative complications from the intestines - 0.05 g/kg every 8 hours, for 5 days before and 7 days after surgery. Maximum doses for adults: single - 2 g, daily - 7 g.

Active ingredient: sulfanilamide monohydrate (sulgin) - 500 mg.
Excipients: potato starch - 96 mg, calcium stearate - 4 mg.

White tablets, flat-cylindrical with a bevel and score line.

Hypersensitivity to the components of the drug or other sulfonamides, glucose-6-phosphate dehydrogenase deficiency, nephrourolithiasis, porphyria, vitamin B12 deficiency anemia, pregnancy, lactation period, children under 3 years of age, hyperbilirubinemia (in children).

To prevent crystalluria during treatment, patients should maintain adequate hydration (2-3 liters/day).
Premature discontinuation of treatment or insufficient doses may lead to the emergence of resistant strains of pathogens.
During treatment, the intake of B vitamins is recommended.

Gastrointestinal system: nausea, vomiting.
Urinary system: crystalluria.
Allergic reactions: urticaria, exfoliative dermatitis.
Others: hypovitaminosis B, leukopenia, neuritis.

Information on overdose is not available.

Reduces the reliability of oral contraceptives.
Benzocaine, procaine reduce antimicrobial activity (release PABA upon hydrolysis).
Non-steroidal anti-inflammatory drugs, hypoglycemic agents (sulfonylurea derivatives), phenytoin, and indirect anticoagulants enhance the severity of the drug's side effects.
Ascorbic acid, hexamethylenetetramine increase the risk of crystalluria. Myelotoxic drugs enhance the manifestations of the drug's hematotoxicity.

Antimicrobial bacteriostatic agent. The mechanism of action is based on antagonism with para-aminobenzoic acid (PABA) and competitive inhibition of dihydropteroate synthase, leading to disruption of tetrahydrofolic acid synthesis, which is necessary for the synthesis of purines and pyrimidines. It inhibits the growth of Escherichia coli and reduces the synthesis of thiamine, riboflavin, and nicotinic acid in the intestine. Sulgin exerts a bacteriostatic effect on Streptococcus spp., Staphylococcus spp., Escherichia coli, Shigella dysenteriae, and Proteus vulgaris.

After oral administration, the drug is minimally absorbed from the gastrointestinal tract, resulting in a high bacteriostatic concentration in the intestine.